Copenhagen, Denmark-based Albumedix has appointed Dr Giles Campion as its chief medical officer and member of the executive team.
Dr Campion will be responsible for the firm’s global development efforts, with a particular focus on its albumin-based drug delivery platform.
He brings over 25 years of drug development experience to the role, most recently as group vice president of BioMarin’s neuromuscular franchise.
Prior to this, Dr Campion was both senior vice president of R&D and chief medical officer of Prosensa Holdings, served as global head of clinical R&D at General Electric Healthcare, and was European head of exploratory clinical development at Novartis.
Peter Rosholm, chief executive of Albumedix, said: “I am delighted to welcome Giles Campion to Albumedix.
“His depth of experience across a broad range of therapeutic indications, drug development track record and expertise in the filings of specialised pharmaceuticals, will be invaluable to us as we move our pre-clinical drug candidates towards the clinic.
“The appointment marks the latest step in our growth strategy as we work to advance breakthroughs in the use of albumin-based technologies in the development of life-changing therapeutics.”